Animal models of the cancer anorexia-cachexia syndrome

被引:72
|
作者
Bennani-Baiti, Nabila [1 ]
Walsh, Declan [1 ,2 ]
机构
[1] Cleveland Clin, Taussig Canc Ctr, Sect Palliat Med & Suppport Oncol, Cleveland, OH 44106 USA
[2] Cleveland Clin, Taussig Canc Ctr, Harry R Horvitz Ctr Palliat Med, Cleveland, OH 44106 USA
关键词
Animal models; Cancer cachexia; Anorexia; Wasting; TUMOR-BEARING RATS; PROTEOLYSIS-INDUCING FACTOR; NECROSIS-FACTOR-ALPHA; LIPID-MOBILIZING FACTOR; GROWTH-FACTOR-I; WEIGHT-LOSS; SKELETAL-MUSCLE; THERAPEUTIC STRATEGIES; PROTEIN-TURNOVER; MESSENGER-RNA;
D O I
10.1007/s00520-010-0972-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and aims Cancer cachexia, a complex wasting syndrome, is common in palliative medicine. Animal models expand our understanding of its mechanisms. A review of cancer cachexia and anorexia animal models will help investigators make an informed choice of the study model. Results and discussion Cancer-anorexia cachexia animal models are numerous. No one is ideal. The choice should depend on the research question. To investigate cancer-anorexia cachexia independent of pro-inflammatory cytokine effects, the MAC16 ADK and XK1 are useful. MAC16 ADK helps study the host's tumor metabolic effects, independent of any anorexia or inflammation. XK1 is both anorectic and cachectic, but data about it is limited. All other models induce a host inflammatory response. The Walker 256 ADK and MCG 101 are best avoided due to excessive tumor growth. Since individual models do not address all aspects of the syndrome, use of a combination seems wise. Suggested combinations: MAC16-ADK (non-inflammatory and non-anorectic) with YAH-130 (inflammatory, anorectic, and cachectic), Lewis lung carcinoma (slow onset anorexia) or prostate adenocarcinoma (inflammatory, anorectic but not cachectic) with YAH-130.
引用
收藏
页码:1451 / 1463
页数:13
相关论文
共 50 条
  • [31] Hypothalamic neuropeptides and appetite response in anorexia-cachexia animal
    Ueta, Yoichi
    Hashimoto, Hirofumi
    Onuma, Etsuro
    Takuwa, Yoh
    Ogata, Etsuro
    ENDOCRINE JOURNAL, 2007, 54 (06) : 831 - 838
  • [32] New drugs for the anorexia-cachexia syndrome.
    Davis M.P.
    Current Oncology Reports, 2002, 4 (3) : 264 - 274
  • [33] Megestrol acetate for the treatment of anorexia-cachexia syndrome
    Berenstein, EG
    Ortiz, Z
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (02):
  • [34] Megestrol acetate for treatment of anorexia-cachexia syndrome
    Ruiz Garcia, Vicente
    Lopez-Briz, Eduardo
    Carbonell Sanchis, Rafael
    Gonzalvez Perales, Jose Luis
    Bort-Marti, Sylvia
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (03):
  • [35] Mediators involved in the cancer anorexia-cachexia syndrome:: past, present, and future
    Argilés, JM
    Busquets, S
    García-Martínez, C
    López-Soriano, FJ
    NUTRITION, 2005, 21 (09) : 977 - 985
  • [36] Anorexia-Cachexia Syndrome in Pancreatic Cancer: Recent Development in Research and Management
    Uomo, Generoso
    Gallucci, Fernando
    Rabitti, Pier Giorgio
    JOURNAL OF THE PANCREAS, 2006, 7 (02): : 157 - 162
  • [37] Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway
    Camps, Carlos
    Iranzo, Vega
    Bremnes, Roy M.
    Sirera, Rafael
    SUPPORTIVE CARE IN CANCER, 2006, 14 (12) : 1173 - 1183
  • [38] Assessing and managing the symptoms associated with the anorexia-cachexia syndrome in cancer patients
    Andrew, I.
    Holden, K.
    Hawkins
    PHARMACY WORLD & SCIENCE, 2007, 29 (03): : 288 - 289
  • [39] Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis
    Yu Bai
    Yunxia Hu
    Yanhua Zhao
    Xizhong Yu
    Junwei Xu
    Zhiyun Hua
    Zhiqiang Zhao
    Supportive Care in Cancer, 2017, 25 : 1651 - 1659
  • [40] Animal models of anorexia and cachexia
    DeBoer, Mark D.
    EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (11) : 1145 - 1155